Healthcare professional and patient perceptions of a new prefilled insulin pen versus vial and syringe

Expert Opinion on Drug Delivery

Volumn 9, Issue 10, 2012, Pages 1181-1196

  Lajara, Rosemarie ^a   Guerrero, German ^b   Thurman, Jerome ^c  

^a Health Center at Plano   (United States)

^b NOVO NORDISK INC   (United States)

^c SSM Saint Charles Medical Group   (United States)

Author keywords

Diabetes; Ease of learning; Ease of teaching; Ease of use; Prefilled insulin pen; Vial and syringe

Indexed keywords

INSULIN;

ADULT; CONTROLLED STUDY; DEVICE SAFETY; DEVICES; DRUG DELIVERY SYSTEM; DRUG USE; FEMALE; HEALTH CARE PERSONNEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LEARNING; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; NURSE; PATIENT PERCEPTION; PERCEPTION; PHYSICIAN; PLUNGER; REVIEW; SYRINGE; TEACHING;

DIABETES MELLITUS; EQUIPMENT DESIGN; HEALTH PERSONNEL; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS; INSULIN; NURSES; PATIENT PREFERENCE; PHYSICIANS; SELF ADMINISTRATION; SYRINGES;

EID: 84866877548     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.721774     Document Type: Review

References (44)

1. Standards of medical care in diabetes-2012. American Diabetes Association. Diabetes Care 2012;35(Suppl 1):S11-63
2. Rydén L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136
3. Rodbard HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13(Suppl 1):1-68
4. Pfützner J, Hellhammer J, Musholt P, et al. Evaluation of dexterity in insulin-treated patients with type 1 and type 2 diabetes mellitus. J Diabetes Sci Technol 2011;5:158-65
5. Keith K, Nicholson D, Rogers D. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump. Clin Pediatr (Phila) 2004;43:69-74
6. Lteif AN, Schwenk WF. Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care 1999;22:137-40
7. Asakura T, Seino H, Nakano R, et al. A comparison of the handling and accuracy of syringe and vial versus prefilled insulin pen (FlexPen). Diabetes Technol Ther 2009;11:657-61
8. Ignaut DA, Schwartz SL, Sarwat S, et al. Comparative device assessments: humalog KwikPen compared with vial and syringe and FlexPen. Diabetes Educ 2009;35:789-98
9. Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1712-25; discussion 1710-1
10. Goldstein HH. Pen devices to improve patient adherence with insulin therapy in type 2 diabetes. Postgrad Med 2008;120:172-9
11. Asche CV, Shane-McWhorter L, Raparla S. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence. Diabetes Technol Ther 2010;12(Suppl 1):S101-8
12. Baser O, Bouchard J, DeLuzio T, et al. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe. Adv Ther 2010;27:94-104
13. IMS Health. Insulin Sales Volume; 2009
14. Perfetti R. Reusable and disposable insulin pens for the treatment of diabetes: understanding the global differences in user preference and an evaluation of inpatient insulin pen use. Diabetes Technol Ther 2010;12(Suppl 1):S79-85
15. Bonafede MM, Kalsekar A, Pawaskar M, et al. A retrospective database analysis of insulin use patterns in insulin-na?̈ve patients with type 2 diabetes initiating basal insulin or mixtures. Patient Prefer Adherence 2010;4:147-56
16. Marcus A. Diabetes care-insulin delivery in a changing world. Medscape J Med 2008;10:120
17. Lee LJ, Li Q, Reynolds MW, et al. Trend analyses of insulin delivery systems in the United States. J Diabetes Sci Technol 2011;5:1116-23
18. Cramer JA, Pugh MJ. The influence of insulin use on glycemic control: how well do adults follow prescriptions for insulin? Diabetes Care 2005;28:78-83
19. Peyrot M, Rubin RR, Kruger DF, et al. Correlates of insulin injection omission. Diabetes Care 2010;33:240-5
20. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-9
21. Peyrot M, Mathews DR, Snoek FJ, et al. An international study of psychological resistance to insulin use among persons with diabetes. Diabetologia 2003;46(Suppl 2):A89
22. Zambanini A, Newson RB, Maisey M, et al. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999;46:239-46
23. Mollema ED, Snoek FJ, Heine RJ, et al. Phobia of self-injecting and self-testing in insulin-treated diabetes patients: opportunities for screening. Diabet Med 2001;18:671-4
24. Hamilton JG. Needle phobia: a neglected diagnosis. J Fam Pract 1995;41:169-75
25. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care 1997;20:292-8
26. Selam JL. Evolution of diabetes insulin delivery devices. J Diabetes Sci Technol 2010;4:505-13
27. Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract 2007;57:455-60
28. Simons WR, Vinod HD, Gerber RA, et al. Does rapid transition to insulin therapy in subjects with newly diagnosed type 2 diabetes mellitus benefit glycaemic control and diabetes-related complications? A German population-based study. Exp Clin Endocrinol Diabetes 2006;114:520-6
29. Rubin RR, Peyrot M. Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care 2008;31:430-2
30. Hemmingsen H, Niemeyer M, Hansen MR, et al. A prefilled insulin pen with a novel injection mechanism and a lower injection force than other prefilled insulin pens. Diabetes Technol Ther 2011;13:1207-11
31. Garg S, Bailey T, Deluzio T, et al. Preference for a new prefilled insulin pen compared with the original pen. Curr Med Res Opin 2011;27:2323-33
32. Oyer D, Narendran P, Qvist M, et al. Ease of use and preference of a new versus widely available prefilled insulin pen assessed by people with diabetes, physicians and nurses. Expert Opin Drug Deliv 2011;8:1259-69
33. Bailey T, Thurman J, Niemeyer M, et al. Usability and preference evaluation of a prefilled insulin pen with a novel injection mechanism by people with diabetes and healthcare professionals. Curr Med Res Opin 2011;27:2043-52
34. Campos C, Lajara R, Deluzio T. Usability and preference assessment of a new prefilled insulin pen versus vial and syringe in people with diabetes, physicians and nurses. Expert Opin Pharmacother 2012;13:1837-46
35. Bohannon NJ, Ohannesian JP, Burdan AL, et al. Patient and physician satisfaction with the Humulin/Humalog Pen, a new 3.0-mL prefilled pen device for insulin delivery. Clin Ther 2000;22:1049-67
36. Korytkowski M, Bell D, Jacobsen C, et al. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003;25:2836-48
37. Nadeau DA, Campos C, Niemeyer M, et al. Healthcare professional and patient assessment of a new prefilled insulin pen versus two widely available prefilled insulin pens for ease of use, teaching and learning. Curr Med Res Opin 2012;28:3-13
38. Toscano D, Brice J, Alfaro C. Usage and perceptions of pen injectors for diabetes management: a survey of type 2 diabetes p atients in the United States. J Diabetes Sci Technol 2012;6:686-94
39. Thurman JE. Insulin pen injection devices for management of patients with type 2 diabetes: considerations based on an endocrinologist's practical experience in the United States. Endocr Pract 2007;13:672-8
40. Pawaskar MD, Camacho FT, Anderson RT, et al. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther 2007;29(Spec No):1294-305
41. Buysman E, Conner C, Aagren M, et al. Adherence and persistence to a regimen of basal insulin in a pre-filled pen compared to vial/syringe in insulin-na?̈ve patients with type 2 diabetes. Curr Med Res Opin 2011;27:1709-17
42. Cobden D, Lee WC, Balu S, et al. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy 2007;27:948-62
43. Lee LJ, Li Q, Reynolds MW, et al. Comparison of utilization, cost, adherence, and hypoglycemia in patients with type 2 diabetes initiating rapid-acting insulin analog with prefilled pen versus vial/syringe. J Med Econ 2011;14:75-86
44. Davis SN, Wei W, Garg S. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting. Endocr Pract 2011;17:845-52